Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Timeline

Start

2022-08-06

Primary completion

2022-12-14

Completion

2022-12-14

Outcome

Met primary endpoint

registry analysis (superiority test); LNZ101 vs Vehicle Ophthalmic Solution; p <0.0001; Odds Ratio (OR) 83.988; Generalized Estimating Equation (GEE) NCT05431543 ↗

registry analysis (superiority test); LNZ100 vs Vehicle Ophthalmic Solution; p <0.0001; Odds Ratio (OR) 102.093; Generalized Estimating Equation (GEE) NCT05431543 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aceclidine	Small molecule	—	—
Subject	Brimonidine	Unknown	—	—

Indications